Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 4, 2005

View Archived Issues

Second interim analysis of phenserine tartrate study in Alzheimer's disease

CholeraGarde reported safe and immunogenic in children and infants

A phase III study confirms the efficacy of telbivudine in compensated chronic hepatitis B

Posiphen given green light to begin phase I

Human Genome Sciences receives milestone payment for GSK-716155

Antiinflammatory compound QR-440 shows disease-modifying potential

BioMarin submits Orapred ODT NDA

Fast track designation for panitumumab for metastatic colorectal cancer

MN-166 enters phase II study for relapsing-remitting MS

Solvay and Berna Biotech sign Aerugen license agreement

Novel compounds inhibit D816 Kit mutation tumor growth

UK-290795: an NK2 antagonist with greater oral absorption

RO-4383596 demonstrates antiangiogenic and antitumor effects

Oracea NDA filed

Peplin raises funds for leukemia program of PEP-005 IV

Kyorin and LG Life Sciences sign memorandum of understanding for KRP-197

Provisional patent application on novel anticancer compounds

Novel analgesic agents claimed in recent patent literature

Therapeutic benefits found for XP-13512 in RLS

Ghrelin increases acute energy intake in malnourished peritoneal dialysis patients

Positive benefits of coenzyme Q10 in Parkinson's disease

Synergistic effects reported for tipifarnib plus taxanes in multiple myeloma

New targets and treatments reported for psychosis, depression, etc.

iNOS inhibitors prepared and tested by Altana Pharma

Antiplatelet effects reported for S-18886 in patients with peripheral artery disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...